Meeting
2013 ASCO Annual Meeting
Open-label, multicenter, single-arm, phase I, dose-dscalation with efficacy tail extension study of vemurafenib in pediatric patients with surgically incurable and unresectable stage IIIc or IV melanoma harboring BRAFV600 mutations (NCT01519323).
Authors
Fariba Navid
St. Jude Children's Research Hospital, Memphis, TN
Fariba Navid , Julia C. Chisholm , Andrea Ferrari , Cynthia E. Herzog , Carlos Rodriguez-Galindo , Axel Hauschild , Kartik Krishnan , Alberto S. Pappo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Clinical Trial Registration Number
NCT01519323
Citation
J Clin Oncol 31, 2013 (suppl; abstr TPS9104)
DOI
10.1200/jco.2013.31.15_suppl.tps9104
Abstract #
TPS9104
Poster Bd #
54A
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Anti-LAG-3 antibody LBL-007 in combination with toripalimab in patients with unresectable or metastatic melanoma: A phase Ⅰ, open-label, multicenter, dose escalation/expansion study.
First Author: Xue Bai
Poster
2016 ASCO Annual Meeting
Phase I study of vemurafenib and heat shock protein 90 (HSP90) inhibitor XL888 in metastatic BRAF V600 mutant melanoma.
First Author: Zeynep Eroglu
Poster
2014 ASCO Annual Meeting
Biomarker study evaluating the combination of dabrafenib (D) with trametinib (T) versus the combination after 8 weeks of monotherapy with dabrafenib or trametinib in patients with metastatic and unresectable stage IIIC or IV melanoma: GSK study 116613.
First Author: Christine Mateus
Poster
2014 ASCO Annual Meeting
A randomized phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM).
First Author: Rahima Jamal